Loading...
Targeting cardiac fibrosis with engineered T cells.
Aghajanian, Haig Kimura, Toru Rurik, Joel G Hancock, Aidan S Leibowitz, Michael S Li, Li Scholler, John Monslow, James Lo, Albert Han, Wei
Aghajanian, Haig
Kimura, Toru
Rurik, Joel G
Hancock, Aidan S
Leibowitz, Michael S
Li, Li
Scholler, John
Monslow, James
Lo, Albert
Han, Wei
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-09-11
Submitted date
Files
Other Titles
Abstract
Fibrosis is observed in nearly every form of myocardial disease1. Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure2. However, clinical interventions and therapies that target fibrosis remain limited3. Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8+ T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts-fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease.
Citation
Nature. 2019;573(7774):430-433. doi:10.1038/s41586-019-1546-z.
Publisher
Journal
PubMed ID
PubMed Central ID
PMC6752964
Additional Links
Embedded video
Type
Article
Other
Other
Language
en
Description
Series/Report no.
ISSN
EISSN
1476-4687
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International